SG11201406185WA - Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases - Google Patents

Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases

Info

Publication number
SG11201406185WA
SG11201406185WA SG11201406185WA SG11201406185WA SG11201406185WA SG 11201406185W A SG11201406185W A SG 11201406185WA SG 11201406185W A SG11201406185W A SG 11201406185WA SG 11201406185W A SG11201406185W A SG 11201406185WA SG 11201406185W A SG11201406185W A SG 11201406185WA
Authority
SG
Singapore
Prior art keywords
disubstitued
pyridine
triazolo
imidazo
modulators
Prior art date
Application number
SG11201406185WA
Inventor
Swaroop Kumar Venkata Satya Vakkalanka
Dhanapalan Nagarathnam
Srikant Viswanadha
Meyyappan Muthuppalaniappan
Govindarajulu Babu
Prashant K Bhavar
Original Assignee
Rhizen Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48093046&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201406185W(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhizen Pharmaceuticals Sa filed Critical Rhizen Pharmaceuticals Sa
Publication of SG11201406185WA publication Critical patent/SG11201406185WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
SG11201406185WA 2012-03-30 2013-02-27 Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases SG11201406185WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1262CH2012 2012-03-30
PCT/IB2013/051577 WO2013144737A2 (en) 2012-03-30 2013-02-27 Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases

Publications (1)

Publication Number Publication Date
SG11201406185WA true SG11201406185WA (en) 2014-11-27

Family

ID=48093046

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201406185WA SG11201406185WA (en) 2012-03-30 2013-02-27 Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases

Country Status (21)

Country Link
US (3) US9815831B2 (en)
EP (1) EP2831073B1 (en)
JP (1) JP6192708B2 (en)
KR (2) KR102164317B1 (en)
CN (2) CN107082779A (en)
AP (1) AP3908A (en)
AU (1) AU2013239398B2 (en)
BR (1) BR112014024251A8 (en)
CA (1) CA2865719C (en)
CL (1) CL2014002604A1 (en)
CO (1) CO7111276A2 (en)
EA (1) EA026412B1 (en)
ES (1) ES2856848T3 (en)
HK (1) HK1204612A1 (en)
IL (1) IL234513B (en)
MX (1) MX359888B (en)
MY (1) MY169268A (en)
NZ (1) NZ629499A (en)
PH (1) PH12014502166B1 (en)
SG (1) SG11201406185WA (en)
WO (1) WO2013144737A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ703111A (en) * 2010-05-17 2016-07-29 Incozen Therapeutics Pvt Ltd Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
JP6192708B2 (en) * 2012-03-30 2017-09-06 ライゼン・ファーマシューティカルズ・エスアー Novel 3,5-disubstituted-3H-imidazo [4,5-B] pyridine compounds and 3,5-disubstituted-3H- [1,2,3] triazolo [4, as C-MET protein kinase modulators 5-B] pyridine compound
GB201321741D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
EP3125920B1 (en) 2014-04-04 2020-12-23 Del Mar Pharmaceuticals Dianhydrogalactitol, diacetyldianhydrogalactitol or dibromodulcitol to treat non-small-cell carcinoma of the lung and ovarian cancer
MA42023B2 (en) * 2015-07-20 2022-01-31 Genzyme Corp Colony Stimulating Factor-1 Receptor (csf-1r) Inhibitors
CN107573340B (en) * 2017-10-23 2020-11-24 江西科技师范大学 Preparation and application of 2-carbamoyl-4-aryl hetero pyridine compound
GB201803892D0 (en) * 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
CA3181537A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
EP4329757A1 (en) * 2021-04-29 2024-03-06 Amgen Inc. Heterocyclic compounds and methods of use
CN114031562A (en) * 2021-10-31 2022-02-11 南京碳硅人工智能生物医药技术研究院有限公司 Process optimization of pyridine derivative with anti-tumor effect

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (en) 1985-06-19 1990-12-20 Ajinomoto Kk HAEMOGLOBIN TIED TO A POLY (ALKENYLENE OXIDE).
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
EP0318512B1 (en) 1986-08-18 1998-06-17 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
ATE156158T1 (en) 1992-04-14 1997-08-15 Cornell Res Foundation Inc MACROMOLECULES BASED ON DENDRITIC POLYMERS AND METHOD FOR THE PRODUCTION
US5646176A (en) 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
MX9708026A (en) 1995-04-20 1997-11-29 Pfizer Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors.
EP0780386B1 (en) 1995-12-20 2002-10-02 F. Hoffmann-La Roche Ag Matrix metalloprotease inhibitors
EP0923585B1 (en) 1996-07-18 2002-05-08 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
EA199900139A1 (en) 1996-08-23 1999-08-26 Пфайзер, Инк. DERIVATIVES OF ARYL SULPHONYLAMINO HYDROXAMIC ACID
ATE272640T1 (en) 1997-01-06 2004-08-15 Pfizer CYCLIC SULFONE DERIVATIVES
JP3765584B2 (en) 1997-02-03 2006-04-12 ファイザー・プロダクツ・インク Arylsulfonylaminohydroxamic acid derivatives
BR9807824A (en) 1997-02-07 2000-03-08 Pfizer Derivatives of n-hydroxy-beta-sulfonyl-propionamide and its use as matrix metalloproteinase inhibitors
IL131123A0 (en) 1997-02-11 2001-01-28 Pfizer Arylsulfonyl hydroxamic acid derivatives
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
PA8469501A1 (en) 1998-04-10 2000-09-29 Pfizer Prod Inc HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO
PA8469401A1 (en) 1998-04-10 2000-05-24 Pfizer Prod Inc BICYCLE DERIVATIVES OF HYDROXAMIC ACID
TWI270546B (en) 1999-02-22 2007-01-11 Bristol Myers Squibb Co C-21 modified epothilones
CA2534027A1 (en) 2003-06-19 2005-01-27 Dennis Drayna Variants of human taste receptor genes
CA2536470A1 (en) 2003-08-15 2005-02-24 Vertex Pharmaceuticals Incorporated Pyrrole compositions useful as inhibitors of c-met
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
WO2005040345A2 (en) 2003-09-24 2005-05-06 Vertex Pharmceuticals Incorporated 4-azole substituted imidazole compositions useful as inhibitors or c-met receptor tyrosine kinase
EP2213661B1 (en) 2003-09-26 2011-07-20 Exelixis Inc. c-Met Modulators and Methods of Use
WO2005051301A2 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Heterocyclic inhibitors of mek and methods of use thereof
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
JP5368701B2 (en) 2004-07-02 2013-12-18 エクセリクシス、インコーポレイテッド c-Met Modulator and Method of Use
WO2006021886A1 (en) 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
CA2577937C (en) 2004-08-26 2010-12-21 Pfizer Inc. Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
PT1786785E (en) 2004-08-26 2010-05-21 Pfizer Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
NZ555236A (en) 2004-11-04 2010-10-29 Vertex Pharma Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
JP2008537748A (en) 2005-04-06 2008-09-25 エクセリクシス、インコーポレイテッド c-Met Modulator and Method of Use
US7470693B2 (en) 2005-04-21 2008-12-30 Bristol-Myers Squibb Company Oxalamide derivatives as kinase inhibitors
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Substituted Amid derivatives & methods of use
WO2007064797A2 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
US7348325B2 (en) 2005-11-30 2008-03-25 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
KR20090007347A (en) 2006-03-22 2009-01-16 버텍스 파마슈티칼스 인코포레이티드 C-met protein kinase inhibitors for the treatment of proliferative disorders
NL2000613C2 (en) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazole pyrazine derivatives.
TW200813021A (en) 2006-07-10 2008-03-16 Merck & Co Inc Tyrosine kinase inhibitors
EP2066676A1 (en) 2006-09-18 2009-06-10 Vertex Pharmaceuticals, Inc. HETEROCYCLIC INHIBITORS OF c-MET AND USES THEREOF
EP2457913B1 (en) * 2006-10-19 2017-04-19 Signal Pharmaceuticals, LLC Heteroaryl compounds, compositions thereof, and methods of treatment therewith
DK2081937T3 (en) 2006-10-23 2012-10-01 Sgx Pharmaceuticals Inc Triazolopyridazine-PROTEINKINASEMODULATORER
MX2009004786A (en) 2006-10-31 2009-06-05 Schering Corp Anilinopiperazine derivatives and methods of use thereof.
WO2008060866A1 (en) 2006-11-14 2008-05-22 Smithkline Beecham Corporation Novel compounds
WO2008078085A1 (en) 2006-12-22 2008-07-03 Astrazeneca Ab Method
CA2675755C (en) 2007-01-19 2015-10-06 Xcovery, Inc. Pyridine and pyridazine derivatives as kinase inhibitors
AU2008217931A1 (en) 2007-02-23 2008-08-28 Eisai R & D Management Co., Ltd. Pyridine or pyrimidine derivative having excellent cell growth inhibition effect and excellent anti-tumor effect on cell strain having amplification of HGFR gene
FR2915198B1 (en) * 2007-04-18 2009-12-18 Sanofi Aventis TRIAZOLOPYRIDINE CARBOXAMIDE AND TRIAZOLOPYRIDINE -CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE.
JP5425060B2 (en) 2007-06-22 2014-02-26 アークル インコーポレイテッド Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for the treatment of cancer
US20110129440A1 (en) 2007-10-29 2011-06-02 Schering Corporation Heterocyclic Urea and Thiourea Derivatives and Methods of Use Thereof
US8394960B2 (en) 2007-10-29 2013-03-12 Merck Sharp & Dohme Corp. Thiazole carboxamide derivatives and their use to treat cancer
WO2009058730A1 (en) 2007-10-29 2009-05-07 Schering Corporation Diamido thiazole derivatives as protein kinase inhibitors
CA2703978A1 (en) 2007-10-29 2009-05-07 Schering Corporation Thiazole derivatives as protein kinase inhibitors
ES2616255T3 (en) * 2008-04-30 2017-06-12 National Health Research Institutes Condensed bicyclic pyrimidine compounds as aurora kinase inhibitors
HUE025504T2 (en) * 2009-12-31 2016-02-29 Hutchison Medipharma Ltd Certain triazolopyrazines, compositions thereof and methods of use therefor
CN102127096A (en) 2009-12-31 2011-07-20 和记黄埔医药（上海）有限公司 Triazole pyridine and triazole pyrazine compound and composition and application thereof
NZ703111A (en) 2010-05-17 2016-07-29 Incozen Therapeutics Pvt Ltd Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
JP6192708B2 (en) * 2012-03-30 2017-09-06 ライゼン・ファーマシューティカルズ・エスアー Novel 3,5-disubstituted-3H-imidazo [4,5-B] pyridine compounds and 3,5-disubstituted-3H- [1,2,3] triazolo [4, as C-MET protein kinase modulators 5-B] pyridine compound
US9887269B2 (en) * 2015-11-30 2018-02-06 Taiwan Semiconductor Manufacturing Company, Ltd. Multi-gate device and method of fabrication thereof

Also Published As

Publication number Publication date
CO7111276A2 (en) 2014-11-10
CL2014002604A1 (en) 2015-04-10
ES2856848T3 (en) 2021-09-28
WO2013144737A2 (en) 2013-10-03
US20150057309A1 (en) 2015-02-26
AU2013239398B2 (en) 2017-09-07
BR112014024251A8 (en) 2018-01-23
JP2015511629A (en) 2015-04-20
KR102164317B1 (en) 2020-10-13
HK1204612A1 (en) 2015-11-27
EP2831073A2 (en) 2015-02-04
EP2831073B1 (en) 2020-12-09
EA026412B1 (en) 2017-04-28
AP2014007966A0 (en) 2014-09-30
AP3908A (en) 2016-11-24
KR20200013111A (en) 2020-02-05
IL234513B (en) 2019-08-29
PH12014502166A1 (en) 2014-12-10
MX2014011750A (en) 2015-10-22
AU2013239398A1 (en) 2014-09-18
CA2865719C (en) 2020-09-22
KR20140144726A (en) 2014-12-19
CN107082779A (en) 2017-08-22
CN104321322A (en) 2015-01-28
MX359888B (en) 2018-10-15
MY169268A (en) 2019-03-20
NZ629499A (en) 2016-05-27
US11066402B2 (en) 2021-07-20
WO2013144737A3 (en) 2013-12-05
JP6192708B2 (en) 2017-09-06
US9815831B2 (en) 2017-11-14
EA201491520A1 (en) 2015-03-31
PH12014502166B1 (en) 2014-12-10
US20180072721A1 (en) 2018-03-15
US20210371416A1 (en) 2021-12-02
CA2865719A1 (en) 2013-10-03

Similar Documents

Publication Publication Date Title
AP3908A (en) Novel 3,5-disubstituted-3H-imidazo[4,5-B]pyridine and 3,5-disubstituted-3H-[1,2,3]triazolo [4,5-B] pyridine compounds as modulators of C-met protein kinases
ZA201906379B (en) 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
IL235819A0 (en) Synthesis of pyrrolo [2,3-b]pyridines
ZA201406148B (en) Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof
ZA201406149B (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use
IL246177B (en) Dihydro- and tetrahydropyrido[3,4-b]pyrazine derivatives as modulators of gpr6
IL238493B (en) Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
AP2013007147A0 (en) Use of substituted 2,3-dihydroimidazo[1,2-C]quinyzolines
PT2935274T (en) 3-oxo-2,3,5,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrimidine derivatives for the treatmetn of respiratory diseases
HK1217658A1 (en) Pyrazolo[1,5-a]pyrimidine-based compounds, compositions comprising them, and methods of their use [15-a]
EP2854528B8 (en) Treatment of solid tumors using coenzyme q10
ZA201406323B (en) Triazolo[4,5-d]pyrimidine derivatives
HK1204610A1 (en) Imidazo [4, 5 - b]pyridine derivatives as alk and jak modulators for the treatment of proliferative disorders alk jak [45-b]
ZA201500865B (en) Process for the preparation of sitagliptin and intermediate compounds
HK1205504A1 (en) Substituted pyrazolo[1,5-a]pyridines, their preparation and use as medicaments [1,5-a]
HK1197244A1 (en) Process for the preparation of 2-phenyl-[1,2,4] triazolo [1,5-a] pyridine derivatives 2--[124][15-a]
PT2870164T (en) Imidazo[2,1-b]thiazole derivatives, their preparation and use as medicaments
IL259166A (en) Novel 4h chromen 4 one compounds as modulators of protein kinases